Dispatch Bio has dosed its first patient in a clinical trial evaluating an experimental virus-based cancer treatment designed to target hard-to-reach solid tumors. The Philadelphia and San Francisco-based biotech firm launched the trial to test the safety and determine a recommended dose of its platform, according to company announcements and local reporting.
How the Flare Platform Targets Solid Tumors
Dispatch Bio’s signature technology, known as the Flare platform, uses an intravenously administered virus engineered to locate tumor cells. Once inside a tumor cell, the virus replicates and tags the cell with a specific target protein called the Flare, which is absent from healthy tissue to prevent toxicity, as explained by Chief Platform Officer Lex Johnson.
At the same time, the platform secretes chemical signals designed to alter the immunosuppressive environment surrounding the tumor. According to Chief Medical Officer Mauro Avanzi, the virus acts as a “Trojan horse.” When the targeted cancer cell is destroyed, it releases thousands of additional viral particles carrying the Flare, creating a chain reaction that spreads the therapeutic effect across multiple tumor sites.
Clinical Trial Focus and Institutional Roots
The initial clinical trial centers on advanced gastrointestinal cancers, including tumors of the stomach, esophagus, and colon.
Dispatch Bio launched a year prior to these trials with $216 million in funding from private investors. The company traces its origins to the University of Pennsylvania, where co-founder Lex Johnson performed PhD research in the laboratories of cell therapy researcher Carl June and cancer researcher Andy Minn. Additional co-founders include Ray Liu, Chris Garcia, and Kole Roybal.
Outlook and Regulatory Hurdles
While the transition to human trials marks a major milestone for the University City-rooted startup, company leaders acknowledge the inherent uncertainties of drug development. Most exploratory scientific efforts do not advance to proof of safety and efficacy in humans, and widespread availability remains years away even under favorable conditions.
According to Lex Johnson, the immediate objective for the firm is gathering clinical data to demonstrate the platform’s viability in patients with significant unmet medical needs. If the treatment proves safe and effective, the company plans to expand investigations into other solid tumor types.